Advances in Neurological Pain Management: Bridging Scientific Innovations and Clinical Practice DOI Open Access

Subodh Raj Khadka,

Pavani Karani,

Neha Gogineni

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Neuronal pain, including neuropathic migraines, and chronic pain syndromes, presents a significant global health challenge. This literature review covers studies conducted until 2024 using major databases, PubMed Google Scholar, with the search terms "Neuropathic Pain/therapy" OR "Chronic "Pain Management/methods" "Neuromodulation/methods" "Spinal Cord Stimulation" "Deep Brain "Transcranial Magnetic Direct Current "Nav1.7 Voltage-Gated Sodium Channel" "Biologics/pharmacology" "Drug Delivery Systems/methods" "Regenerative Medicine/methods" "Stem Cell Transplantation/methods" "Platelet-Rich Plasma/therapeutic use" "Tissue Engineering/methods" "Biomarkers/metabolism" "Machine Learning" "Precision Medicine." explores contemporary advancements in neurological therapy, emphasizing analytical that translate into clinical applications. The research foundation is built on modern examining mechanisms, pharmaceutical innovations, neuromodulation strategies, personalized management, regenerative medicine. Notable include neuroinflammation research, molecular genetic factor discoveries, development of selective Nav1.7 inhibitors, biologics, advanced drug delivery systems. Neuromodulation techniques, both invasive (e.g., deep brain stimulation (DBS), spinal cord (SCS)) noninvasive transcranial direct current (tDCS), magnetic (TMS)), play crucial role modulation. Regenerative approaches, stem cell platelet-rich plasma (PRP), tissue engineering, offer promising solutions for repair symptom relief. Additionally, genomic data, biomarkers, machine learning enhance precision management. Ethical considerations regarding treatment accessibility opioid alternatives remain critical, particularly Hispanic Americans facing language barriers programs like Optum. Selective serotonin reuptake inhibitors (SSRIs) continue to be widely used mental treatment. In conclusion, convergence translational innovative therapies, medicine marks transformative era improving patient outcomes quality life.

Language: Английский

Cancer metabolism and carcinogenesis DOI Creative Commons
Jianqiang Yang, Chloe Shay, Nabil F. Saba

et al.

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Jan. 29, 2024

Abstract Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their metabolic pathways, allowing adapt different microenvironments therapeutic interventions. This refers heterogeneity, in which cell populations use pathways sustain survival proliferation impact response conventional therapies. Thus, targeting heterogeneity represents innovative avenue with potential overcome treatment resistance improve outcomes. review discusses patterns developmental stages, summarizes molecular mechanisms involved intricate interactions within metabolism, highlights clinical vulnerabilities as a promising regimen. We aim unravel complex characteristics develop personalized approaches address distinct traits, ultimately enhancing patient

Language: Английский

Citations

35
Hallmarks of cancer resistance DOI Creative Commons
Muhammad Tufail,

Jia-Ju Hu,

Jie Liang

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(6), P. 109979 - 109979

Published: May 15, 2024

This review explores the hallmarks of cancer resistance, including drug efflux mediated by ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized Warburg effect, and dynamic interplay between cells mitochondria. The role stem (CSCs) in treatment resistance regulatory influence non-coding RNAs, such as long RNAs (lncRNAs), microRNAs (miRNAs), circular (circRNAs), are studied. chapter emphasizes future directions, encompassing advancements immunotherapy, strategies to counter adaptive integration artificial intelligence for predictive modeling, identification biomarkers personalized treatment. comprehensive exploration these provides a foundation innovative therapeutic approaches, aiming navigate complex landscape enhance patient outcomes.

Language: Английский

Citations

19
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies DOI Creative Commons
Yan-Ruide Li,

Ying Fang,

Shaoqiang Niu

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 1, 2025

Abstract Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. Current autologous CAR-T therapies also face manufacturing patient selection issues, underscoring the need off-the-shelf products. In this study, we characterize primary samples identify a unique therapeutic opportunity CAR-engineered invariant natural killer (CAR-NKT) Using stem gene engineering clinically guided culture method, generate allogeneic CD33-directed CAR-NKT cells with high yield, purity, robustness. preclinical mouse models, exhibit strong BM homing effectively target blast cells, including CD33-low/negative leukemia progenitor Furthermore, synergize hypomethylating agents, enhancing tumor-killing efficacy. These show minimal off-tumor toxicity, reduced graft-versus-host disease cytokine release syndrome risks, resistance to allorejection, highlighting their substantial potential malignancies.

Language: Английский

Citations

3
Boosting CAR-T cell therapy through vaccine synergy DOI Creative Commons
Yan-Ruide Li,

Zibai Lyu,

Xinyuan Shen

et al.

Trends in Pharmacological Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological cancers. However, achieving comparable success in solid tumors remains challenging. Factors contributing to these limitations include scarcity of tumor-specific antigens (TSAs), insufficient CAR-T infiltration, and immunosuppressive tumor microenvironment (TME). Vaccine-based strategies are emerging as potential approaches address challenges, enhancing expansion, persistence, antitumor efficacy. In this review, we explore diverse vaccine modalities, including mRNA, peptide, viral vector, dendritic (DC)-based vaccines, their roles augmenting responses. Special focus is given recent clinical advancements combining mRNA-based vaccines with genitourinary addition, discuss crucial considerations optimizing dosing, scheduling, delivery maximize synergy, aiming refine combination strategy improve efficacy safety.

Language: Английский

Citations

2
Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies DOI Open Access
Mohamed El‐Tanani, Syed Arman Rabbani, Shakta Mani Satyam

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 382 - 382

Published: Jan. 24, 2025

Cancer stem cells (CSCs) play a central role in tumor progression, recurrence, and resistance to conventional therapies, making them critical focus oncology research. This review provides comprehensive analysis of CSC biology, emphasizing their self-renewal, differentiation, dynamic interactions with the microenvironment (TME). Key signaling pathways, including Wnt, Notch, Hedgehog, are discussed detail highlight potential as therapeutic targets. Current methodologies for isolating CSCs critically examined, addressing advantages limitations advancing precision medicine. Emerging technologies, such CRISPR/Cas9 single-cell sequencing, explored transformative unraveling heterogeneity informing strategies. The also underscores pivotal TME supporting survival, promoting metastasis, contributing resistance. Challenges arising from CSC-driven dormancy analyzed, along strategies mitigate these barriers, novel therapeutics targeted approaches. Ethical considerations integration artificial intelligence designing CSC-specific therapies essential elements future manuscript advocates multi-disciplinary approach that combines innovative advanced therapeutics, collaborative research address complexities CSCs. By bridging existing gaps knowledge fostering advancements personalized medicine, this aims guide development more effective cancer treatment strategies, ultimately improving patient outcomes.

Language: Английский

Citations

1
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

et al.

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

Citations

1
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

6
Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation DOI Creative Commons
Marta Delgado-Arija, Patricia Genovés, Lorena Pérez-Carrillo

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Feb. 1, 2024

Abstract Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction its levels pathological conditions associated with acute processes been observed. We aimed to identify FAP cardiac tissue expression and relationship the main fibrosis-related signaling pathways, compare plasma chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq left ventricle from patients (n = 57) controls 10). Western blotting immunohistochemistry used explore localization tissue. ELISA was performed examine 48), 15) control samples 7). Results overexpression is related of molecules directly involved fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 COL3A1 ( P < 0.001), inversely pro- antifibrotic microRNAs, respectively. The observed not reflected plasma. Circulating lower than 0.05), while did show significant changes. clinical variables analyzed, functional class or etiology, do affect concentrations. Conclusions determined that tissue, fibrosis pathways well microRNAs. Additionally, phase decreases despite upregulation regardless other conditions. Graphical abstract

Language: Английский

Citations

5
Cancer Stem Cells from Definition to Detection and Targeted Drugs DOI Open Access
Barbara Ruszkowska-Ciastek, Katarzyna Kwiatkowska,

Dorinda Marques‐da‐Silva

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3903 - 3903

Published: March 31, 2024

Cancers remain the second leading cause of mortality in world. Preclinical and clinical studies point an important role cancer/leukaemia stem cells (CSCs/LSCs) colonisation at secondary organ sites upon metastatic spreading, although precise mechanisms for specific actions are still not fully understood. Reviewing present knowledge on crucial CSCs/LSCs, their plasticity, population heterogeneity treatment failures cancer patients is timely. Standard chemotherapy, which acts mainly rapidly dividing cells, unable to adequately affect CSCs with a low proliferation rate. One proposed CSC resistance anticancer agents fact that these can easily shift between different phases cell cycle response typical stimuli induced by drugs. In this work, we reviewed recent CSC/LSC alterations associated disease recurrence, systematised functional assays, markers, novel methods screening. This review emphasises CSCs’ involvement progression metastasis, as well targeting synthetic natural compounds aiming elimination or modulation stemness properties.

Language: Английский

Citations

5
Extracellular Vesicles in Breast Cancer: From Intercellular Communication to Therapeutic Opportunities DOI Creative Commons
Muttiah Barathan, Sook Luan Ng, Yogeswaran Lokanathan

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(5), P. 654 - 654

Published: May 14, 2024

Breast cancer, a multifaceted and heterogeneous disease, poses significant challenges in terms of understanding its intricate resistance mechanisms devising effective therapeutic strategies. This review provides comprehensive overview the landscape extracellular vesicles (EVs) context breast highlighting their diverse subtypes, biogenesis, roles intercellular communication within tumour microenvironment (TME). The discussion spans various aspects, from EVs stromal cells cancer to influence on angiogenesis, immune response, chemoresistance. impact EV production different culture systems, including two dimensional (2D), three (3D), organoid models, is explored. Furthermore, this delves into potential presenting emerging strategies such as engineered for gene delivery, nanoplatforms targeted chemotherapy, disrupting derived treatment approach. Understanding these complex interactions milieu crucial identifying developing new targets.

Language: Английский

Citations

5